Kriya Therapeutics vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Kriya Therapeutics is a gene therapy company using AAV vector engineering to develop one-time treatments for chronic diseases including diabetes and hemophilia; raised $270M total including a $150M Series C in 2022 led by Premji Invest;
About
Kriya Therapeutics is a gene therapy company founded in 2019 by Saket Bhargava and Chintan Shah, headquartered in Research Triangle Park, North Carolina. The company is building a platform for adeno-associated virus (AAV) gene therapy specifically targeting chronic metabolic and cardiovascular diseases — conditions where a single gene therapy treatment could potentially replace a lifetime of injectable or oral medications. Kriya's therapeutic thesis is that gene therapy, historically applied to rare genetic diseases, can be extended to larger-prevalence conditions like type 2 diabetes, obesity, and lipid disorders — unlocking much larger commercial markets than orphan drug gene therapy programs.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.